Forte Biosciences (FBRX) Stock Price, News & Analysis

Company Overview

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing microbiome-based therapies for inflammatory and immune-mediated skin diseases. The company’s approach involves using naturally occurring microorganisms and their biological effects to help restore healthy skin function and address disease-related inflammation.

Forte’s lead product candidate has been FB-401, a topical live biotherapeutic product based on Roseomonas mucosa, a naturally occurring bacterium found on human skin. The program was developed primarily for the potential treatment of atopic dermatitis, a chronic inflammatory skin condition. Forte has evaluated FB-401 in clinical studies and has used the results to guide its research and development strategy.

Founded in 2016, Forte Biosciences is headquartered in Dallas, Texas. The company’s activities have primarily centered on developing therapies for dermatological and immune-related conditions, with its research directed toward patients in markets where these diseases represent significant unmet medical needs.

Key Stats

• Today's Range: $76.99 to $76.99
• 50-Day Range: $47.49 to $76.99
• 52-Week Range: $10.11 to $77.20
• Volume: N/A
• Average Volume: 1.86 million shs
• Market Capitalization: $1.63 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $71.67
• Consensus Rating: Hold

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/04/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:FBRX
• CIK: 1419041
• Web: www.fortebiorx.com
• Phone: (310) 618-6994
• Fax: N/A
• Employees: 5
• Year Founded: 2001

Price Target and Rating

• Average Price Target for Forte Biosciences: $71.67
• High Price Target: $77.00
• Low Price Target: $61.00
• Potential Upside/Downside: -6.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$69.38 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -94.82%
• Return on Assets: -77.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.01
• Quick Ratio: 10.01

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.66 per share
• Price / Book: 8.89

Miscellaneous

• Outstanding Shares: 21,229,000
• Free Float: 20,295,000
• Market Cap: $1.63 billion
• Optionable: Optionable
• Beta: 2.62